布地奈德喷雾剂联合脱敏疗法治疗过敏性鼻炎的效果

摘要

Objective To investigate the efficacy of budesonide sprays combined with desensitization treatment for allergic rhinitis.Methods Total of 128 allergic rhinitis patients from in Baoji Second People′s Hospital from Oct.2014 to Oct.2015 were included in the study and divided into a combined treatment group (n=64) and a budesonide group(n=64) with balloting method.The budesonide group was treated with budesonide spray (1-2 spray every time,twice a day,for 3 months) ,the combined treatment group was given desensitization therapy on the basis of the budesonide group, for 6 months.The therapeutic effect, clinical symptoms and immune function before and after treatment of the two groups were compared.Results The total effective rate of the combined treatment group was higher than the budesonide group[96.87%(62/64) vs 81.25%(52/64)](P<0.05).After treatment,the scores of nasal discharge,nasal obstruction,sneezing, rhinocnesmus of the combined treatment group were lower than the budesonide group[(0.8 ±0.1) score, (0.7 ±0.1) score,(0.8 ±0.1) score,(0.8 ±0.2) score vs (2.0 ±0.2) score,(1.6 ±0.4) score, (1.6 ±0.4) score,(1.8 ±0.3) score,P <0.01].The CD4 +Th17 cell ratio of the combined treatment group was lower than the budesonide group[(1.1 ±0.2)% vs (1.8 ±0.3)%],Th17/Treg,CD4 +CD25 +Treg cells ratio were higher than the budesonide group [ ( 32.8 ±4.2 )%, ( 27.0 ±3.0 )% vs ( 10.8 ± 0.2)%,(7.0 ±0.6)%](P<0.01).Conclusion Budesonide sprays combined with desensitization ther-apy can effectively improve the immune function and clinical symptoms of the patients with allergic rhinitis , and enhance the therapeutic effect.%目的：探讨布地奈德喷雾剂联合脱敏疗法治疗过敏性鼻炎的疗效。方法选择2014年10月至2015年10月在宝鸡市第二人民医院耳鼻喉科就诊的128例过敏性鼻炎患者为研究对象，采用抽签法将患者分为联合治疗组（n＝64）和布地奈德组（n＝64）。布地奈德组应用布地奈德喷雾剂（每次1～2吸，每日2次，持续治疗3个月）治疗，联合治疗组在布地奈德组的基础上应用脱敏疗法，治疗时间为6个月，比较两组患者的临床疗效以及治疗前后临床症状和免疫功能的改善情况。结果联合治疗组的总有效率为96.87％（62／64），布地奈德组的总有效率为81.25％（52／64），联合治疗组总有效率高于布地奈德组，差异有统计学意义（ P＜0.05）。治疗后，联合治疗组患者流涕、鼻塞、喷嚏、鼻痒等症状评分分别为（0.8±0.1）分、（0.7±0.1）分、（0.8±0.1）分、（0.8±0.2）分，低于布地奈德组的（2.0±0.2）分、（1.6±0.4）分、（1.6±0.4）分、（1.8±0.3）分]，差异有统计学意义（P＜0.01）；治疗后，联合治疗组患者 CD4＋Th17细胞比率低于布地奈德组[（1.1±0.2）％比（1.8±0.3）％]，Th17／Treg、CD4＋CD2＋5 Treg细胞比率高于布地奈德组[（32.8±4.2）％比（10.8±0.2）％、（27.0±3.0）％比（7.0±0.6）％]，差异有统计学意义（P＜0.01）。结论布地奈德喷雾剂联合脱敏疗法能有效改善过敏性鼻炎患者的免疫功能及临床症状，提高患者的治疗效果。